Analyst Expectations for Genmab's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided a mix of bullish and bearish ratings for Genmab (NASDAQ:GMAB) in the last quarter. The average price target is $42.29, which is higher than the current price of $37.99. This average has increased by 28.15% from the previous average price target of $33.00.
September 05, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings for Genmab may lead to volatility in the short term. The average price target suggests potential upside.
The mixed analyst ratings indicate differing opinions about the company's performance, which could lead to volatility in the stock price. However, the average price target is higher than the current price, suggesting potential upside.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100